The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Individualizing treatment in transplant-eligible & transplant-ineligible NDMM
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, gives an overview of how treatment approaches have advanced in patients with transplant-eligible and transplant-ineligible newly diagnosed multiple myeloma (NDMM). With the introduction of doublet, triplet, and quadruplet regimens, there are a variety of options for patients, and Prof. Leleu highlights the importance of tailoring regimens for each individual. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
